Antifungal drug targets gut fungus in Crohn's patients with genetic risk
NCT ID NCT04966585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the antifungal drug posaconazole in people with active Crohn's disease who carry a specific gene variant (CARD9 S12N). The goal was to see if reducing a type of fungus in the gut could lower inflammation and improve symptoms. The trial was stopped early and included only 10 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARD9 S12N RISK ALLELE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center (CSMC)
Los Angeles, California, 90048, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a probiotic enema heal the gut lining in ulcerative colitis?
- Amniotic cell secretions may fight gut inflammation and scarring — a lab study puts them to the test
- Could a diet change calm IBD by reshaping gut bacteria?
- New staining technique could sharpen healing assessment in IBD
- Medical records reveal clues to treating stubborn inflammatory bowel disease
- Could poop transplants spare kids with Crohn's from strong drugs?